Last reviewed · How we verify
NCT04804618
Proteomics Study of Mild Cognitive Impairment and Alzheimer's Disease
trial in Alzheimer Disease, Early Onset in 650 participants. Currently enrolling.
30 June 2026
Quick facts
| Lead sponsor | Guangzhou University of Traditional Chinese Medicine |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 650 |
| Start date | 1 June 2021 |
| Primary completion | 30 June 2026 |
| Estimated completion | 30 June 2026 |
| Sites | 1 location across China |
Conditions studied
- Alzheimer Disease, Early Onset — all drugs for Alzheimer Disease, Early Onset →
- Protein; Disease — all drugs for Protein; Disease →
Sponsor
Guangzhou University of Traditional Chinese Medicine
Who can join
55 and older, any sex, with Alzheimer Disease, Early Onset or Protein; Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study intends to adopt standardized and rigorous cross-sectional research, collect biological specimens (including blood, feces, urine, saliva and tongue coating) from eligible subjects, and use liquid chromatography/mass spectrometry (LC-MS/MS) technology to explore early warning indicators of protein in patients with mild cognitive impairment and Alzheimer's disease
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04804618
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Alzheimer Disease, Early Onset
Currently open trials in the same condition.
- NCT06814730 — A Study to Assess THN391 in Subjects With Alzheimer's Disease · Phase 1 · recruiting
- NCT06688968 — Neuropsychological Profiles and Musical Engagement in Parkinson's and Alzheimer's Disease · NA · recruiting
- NCT06668610 — A Multifocal TDCS-EEG Protocol for Improving Symptoms of Mild Cognitive Impairment and Early Dementia · NA · recruiting
- NCT06268886 — Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Partici · Phase 2 · active not recruiting
- NCT05983575 — A Pivotal Study of LIPUS-Brain in Patients With Early Alzheimer's Disease · Phase 3 · active not recruiting
Other Guangzhou University of Traditional Chinese Medicine trials
Trials by the same sponsor.
- NCT07348965 — Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis · NA · recruiting
- NCT07121088 — Traditional Chinese Medicine Intervention for Ischemic Cerebrovascular Disease and Diabetes Mellitus: An Efficacy Compar · Phase 4 · not yet recruiting
- NCT07104422 — An Epidemiological and Long-Term Endpoint Registry Study on Disease-Syndrome Correlation Patterns in Comorbid Population · not yet recruiting
- NCT07088523 — Traditional Chinese Medicine Intervention for Ischemic Cardiovascular Disease Comorbid With Diabetes Mellitus: An Effica · Phase 4 · not yet recruiting
- NCT07120724 — Real-World Study on Chinese Medicine for Treating Chikungunya Fever · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04804618 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangzhou University of Traditional Chinese Medicine
- Last refreshed: 15 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04804618.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing